Artia Global Partners as of Sept. 30, 2023
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 27 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Novo-nordisk A S Adr (NVO) | 25.8 | $62M | 682k | 90.94 | |
| Merck & Co (MRK) | 14.1 | $34M | 329k | 102.95 | |
| Argenx Se Sponsored Adr (ARGX) | 10.1 | $24M | 49k | 491.63 | |
| Eli Lilly & Co. (LLY) | 5.8 | $14M | 26k | 537.13 | |
| Abbvie (ABBV) | 5.6 | $14M | 91k | 149.06 | |
| Astrazeneca Sponsored Adr (AZN) | 5.4 | $13M | 191k | 67.72 | |
| Seagen | 4.5 | $11M | 51k | 212.15 | |
| Roivant Sciences SHS (ROIV) | 4.4 | $11M | 914k | 11.68 | |
| 89bio (ETNB) | 3.0 | $7.2M | 466k | 15.44 | |
| BioMarin Pharmaceutical (BMRN) | 2.9 | $6.9M | 79k | 88.48 | |
| Sarepta Therapeutics (SRPT) | 2.9 | $6.9M | 57k | 121.22 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.6 | $6.4M | 18k | 347.74 | |
| Axsome Therapeutics (AXSM) | 2.6 | $6.1M | 88k | 69.89 | |
| Neurocrine Biosciences (NBIX) | 2.1 | $5.1M | 45k | 112.50 | |
| Viking Therapeutics (VKTX) | 1.8 | $4.2M | 384k | 11.07 | |
| Alnylam Pharmaceuticals (ALNY) | 1.2 | $2.8M | 16k | 177.10 | |
| Intra Cellular Therapies (ITCI) | 0.9 | $2.2M | 42k | 52.09 | |
| Vaxcyte (PCVX) | 0.8 | $2.0M | 39k | 50.98 | |
| Protagonist Therapeutics (PTGX) | 0.8 | $1.9M | 112k | 16.68 | |
| Pliant Therapeutics (PLRX) | 0.7 | $1.7M | 100k | 17.34 | |
| Charles River Laboratories (CRL) | 0.6 | $1.4M | 6.9k | 195.98 | |
| Thermo Fisher Scientific (TMO) | 0.4 | $1.1M | 2.1k | 506.17 | |
| Waters Corporation (WAT) | 0.3 | $780k | 2.8k | 274.21 | |
| Tyra Biosciences (TYRA) | 0.3 | $623k | 45k | 13.77 | |
| Cymabay Therapeutics | 0.3 | $615k | 41k | 14.91 | |
| Biomea Fusion (BMEA) | 0.1 | $350k | 26k | 13.76 | |
| Gritstone Oncology Ord (GRTS) | 0.1 | $164k | 95k | 1.72 |
